Latest JNJ news

2026 2H Healthcare Dividend Roundup: Johnson & Johnson Outshines AbbVie

Seeking Alpha · Wed, 23 Sep 2026 10:14:01 -0400

Johnson & Johnson trades at a 30% P/E premium to AbbVie (24.2x vs. 18.8x on FY1 basis). The premium is further amplified on a PEGY basis (4.80x vs. 2.33x) when yield and growth are factored in. However, JNJ's premium is well justified by its conservative balance sheet and superior capital allocation flexibility.

New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma

PRNewsWire · Wed, 23 Sep 2026 09:46:00 -0400

Analysis shows ~87% of patients treated with TECVAYLI® plus DARZALEX FASPRO® as early as second line were estimated to have comparable mortality risk to the general population A separate analysis shows the survival benefit was driven by a 90% reduction in the risk of multiple myeloma progression versus standard of care, with no significant difference in rates of non-relapse mortality Johnson & Johnson is advancing a differentiated multiple myeloma portfolio designed to deliver deeper, more durable disease control and improve long-term outcomes for patients RARITAN, N.J., Sept. 23, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who had received 1-3 prior lines of therapy.1,2 Using a relative survival mixture cure model (MCM) and actual progression-free survival (PFS) and overall survival (OS) data from the trial, statistical modeling estimated that ~87% of patients treated with TECVAYLI® plus DARZALEX FASPRO ® (Tec-Dara) may experience a mortality risk and projected life expectancy similar to an age-matched general population.1 Modeling further predicted that median overall survival with Tec-Dara would be nearly four-fold longer than with the standard of care (SOC) comparator in the study, dexamethasone with pomalidomide or bortezomib (DPd/DVd).

4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout

24/7 Wall Street · Wed, 23 Sep 2026 09:01:41 -0400

Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions.

JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania Study

Zacks Investment Research · Tue, 22 Sep 2026 12:16:05 -0400

J&J's Caplyta shows rapid and significant improvement in bipolar mania symptoms in a pivotal phase III study.

Johnson & Johnson May Offload Its Orthopedics Unit for $20 Billion -- and Investors Shouldn't Miss What That Could Signal

The Motley Fool · Mon, 21 Sep 2026 19:15:00 -0400

Johnson & Johnson announced plans to spin off its orthopedics business in late 2025. In early 2026, J&J was reported to be in talks with private equity firms about a sale.

Johnson & Johnson Drug Shows Improved Mania Symptoms in Bipolar Patients

Benzinga · Mon, 21 Sep 2026 13:08:49 -0400

Johnson & Johnson (NYSE:JNJ) on Monday reported topline results from its Phase 3 study evaluating Caplyta (lumateperone) for adults experiencing manic episodes linked to bipolar I disorder.

J&J's Caplyta meets main goal of bipolar mania study

Reuters · Mon, 21 Sep 2026 08:50:15 -0400

Johnson & Johnson said on Monday its experimental use of Caplyta for bipolar mania met the main goal of a late-stage study, bringing the drug a step ‌closer to expanding beyond its currently approved uses.

Market information is provided for research and visualization and is not investment advice.